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Received April 5, 2012; accepted July 3, 2012AbstractBackground: It is known that the pharmacokinetic profile of proton pump inhibitors (PPIs) after postprandial administration may differ among
PPIs. The purpose of this study was to compare the inhibitory effects of gastric acid secretion by PPIs administered after a meal, based on a 24-
hour intragastric pH monitoring.
Methods: Ten healthy men who provided written informed consent participated in the study. They were given a 20-mg omeprazole tablet and
a 30-mg lansoprazole orally dispersing tablet in a two-way crossover manner. At baseline, the anti-HP-IgG antibody levels in blood and the
pepsinogen (PG) I/II ratio were measured. Participants were given a standardized meal and 200 mL of water at 9:30 AM, 13:30 PM, and 18.30 PM.
Participants took the PPI after breakfast.
Results: Two of the ten participants tested positive for Helicobacter pylori infection. The PG I/II ratio indicated negative gastric atrophy in all the
participants. The percentage 24-hour intragastric pH > 4 holding times (median, range) with omeprazole and lansoprazole were 29.3,
19.3e50.0% and 27.8, 13.0e42.3%, respectively, which shows that with the administration of omeprazole, the pH was maintained at >4 for
a longer period ( p < 0.05). Each median intragastric pH value per hour at 3, 17, and 18 hours after a dose of omeprazole was significantly higher
than that of lansoprazole ( p < 0.05).
Conclusion: Compared with lansoprazole, a single postprandial dose of omeprazole showed a more rapid and sustained acid-inhibitory effect.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Proton pump inhibitors (PPIs) are potent inhibitors of
gastric acid secretion, and are used as a first-line treatment in
patients with gastroesophageal reflux disease (GERD) and
other acid-related diseases. Because PPIs are activated in the
presence of a high concentration of hydrogen ions, preprandial
administration is recommended for PPIs in Western countries
so that the peak blood concentration of the PPIs occurs when
gastric acid is actively secreted by the parietal cells of the
gastric mucosa after the meal.1 In Japan, by contrast,* Corresponding author. Dr. Yasushi Funaki, Department of Gastroenter-
ology, Aichi Medical University, School of Medicine, 1-1, Yazakokarimata,
Nagakute, Aichi 480-1195, Japan.
E-mail address: momomaru@aichi-med-u.ac.jp (Y. Funaki).
1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.11.006a questionnaire survey on the timing of administering PPIs that
included 127 gastroenterologists revealed following: 79%
recommended postbreakfast, 13% recommended postevening
meal, 3% recommended at bedtime, and 6% recommended
prebreakfast.2 Another report has described that many clini-
cians recommend postbreakfast administration of PPIs, and
approximately 50% of patients with GERD do not take PPIs at
an appropriate time of the day.3 The inhibitory effect of PPIs
on gastric acid secretion is known to correlate with the area
under the blood concentrationetime curve. Although the
absorption of omeprazole is not affected when administered
before or after a meal,4,5 the absorption of lansoprazole is
reduced when administered after a meal,6,7 which indicates
that the pharmacokinetic profile after postprandial adminis-
tration may differ among PPIs.hinese Medical Association. All rights reserved.
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a single postprandial dose of 20-mg omeprazole or 30-mg
lansoprazole (orally disintegrating tablet) was administered
to determine their effects on intragastric pH by 24-hour
intragastric pH monitoring.
2. Methods2.1. ParticipantsHealthy Japanese men who volunteered to participate in
this study were recruited between July 2010 and June 2011.
Exclusion criteria included having upper gastrointestinal
symptoms, a history of upper gastrointestinal surgery, history
of gastrointestinal or hepatobiliary diseases, and use of
medications known to influence gastric acid secretion.
This study was conducted in accordance with the Decla-
ration of Helsinki and the Japanese Ethical Guidelines on
Human Genome and Genetic Analyses, and was approved by
the Ethics Committee of Aichi Medical University Hospital,
Aichi, Japan. Written informed consent was obtained from all
the participants before their participation.2.2. Helicobacter pylori infectionThe participants underwent blood tests to determine the
status of their Helicobacter pylori infection (serum anti-H.
pylori antibody) and the degree of gastric mucosal atrophy
[pepsinogen (PG) I level, PG II level, and PG I/II ratio] (SRL,
Inc., Tokyo, Japan). PG I/II ratio positively correlated with
acid output.8 Participants with a PG I/II ratio < 2.0 were
considered to have positive gastric mucosal atrophy.2.3. Twenty-four-hour intragastric pH monitoringThe participants were not allowed to eat from 21:00 PM the
day before the test. Before each recording session, a glass
electrode (Multi-use pH catheter, SYNECTICS MEDICAL,
Stockholm, Sweden) was calibrated in buffer solutions at pH
1.07 and 7.01. At 9:00 AM, the pH electrode was inserted
through the nose and the tip was fluoroscopically positioned
in the upper portion of the gastric corpus (10 cm below the
gastroesophageal junction) and connected to a portable
digital recorder (Digitrapper pH400, Sierra ScientificTable 1
Characteristics of the participants who took part in this study.
Participant Age Body mass index Helicobacter pylori
1 34 23.6 
2 44 20.2 
3 36 22.5 
4 31 22.4 
5 25 20.4 
6 25 21.5 D
7 22 23.3 
8 20 22.5 
9 21 20.6 
10 32 21.8 DInstruments, Los Angeles, CA, USA). At 9:30 AM, after the
insertion of pH electrode, the participants were given a stan-
dardized meal for breakfast. From this time onward,
measurement of the intragastric pH commenced that
continued for 24 hours. The participants were provided
standardized meals [total calories: 1102 kJ/d (proteins,
14.6 g; lipids, 16.9 g; and carbohydrates, 222.8 g)] and
200 mL of tap water at fixed times (lunch at 13:30 PM, dinner
at 18:30 PM, breakfast at 9:30 AM). They also had to drink
200 mL of water at 15:00 PM and 22:00 PM. No restrictions
were imposed in terms of daily activities. The pH values
obtained were analyzed using the commercially available
EsopHogram software program (Gastrosoft, Stockholm).2.4. Study design and procedureThis was a prospective, open-label, two-way crossover
study. Each participant received either 20-mg omeprazole
(OMEPRAL; AstraZeneca, Osaka) or a 30-mg orally
dispersing (OD) tablet of lansoprazole (TAKEPRON; Takeda
Pharmaceutical Co., Tokyo). PPIs were given to the participant
immediately after breakfast. The 20-mg omeprazole tablet was
given with approximately 100 mL of water. The 30-mg OD
tablet of lansoprazole was given after drinking approximately
100 mL of water. The drugs were given with an interval of at
least 1 week to allow for the excretion of the previously
administered PPI. Intragastric pH was monitored two times in
each participant, that is, once with omeprazole and the other
with lansoprazole. The inhibitory effect of gastric acid secre-
tion was compared between the two drugs using the pH data
recorded every 10 seconds, specifically regarding the
percentage (%) of total time of pH > 4 (pH > 4 holding time)
during the 24-hour period and the median intragastric pH
per hour.2.5. Statistical analysisThe percent of pH > 4 holding time during 24 hours and
median intragastric pH per hour after dosing of each drug were
compared by the Wilcoxon signed-rank test. Statistical anal-
ysis was performed using StatView 4.54 (Abacus Concepts,
Berkeley, CA, USA). A p value <0.05 was considered to be











Fig. 1. Boxewhisker plots of the percent of time that intragastric pH was
above 4.0 during 24 hours after the administration of 20-mg omeprazole and
30-mg lansoprazole orally dispersing to healthy participants (*p < 0.05 by
Wilcoxon signed-rank test between the two groups). In this boxewhisker plot,
the median values are indicated as the transverse line within the box, the
interquartile range as the vertical extent of the box, and total range as the
whiskers. Me ¼ median.
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A total of 10 healthy volunteers aged between 20 and 44
years (mean: 29 years) with a body mass index of
20.2e23.6 kg/m2 (mean: 21.9 kg/m2) and having no history of
eradication therapy participated in this study. H. pylori
infection was detected in two of the ten participants. The PG I/
II ratio was found to be negative in all the participants (Table
1). No adverse events occurred during the study, which was
completed according to the protocol by all the participants.
The percentage of pH > 4 holding times after the admin-
istration of each PPI is shown in Fig. 1. After theFig. 2. Profiles of 24-hour intragastric pH (median pH per hour) in healthy particip
dispersing (OD) after breakfast (*p < 0.05 by Wilcoxon signedl-rank test between
inhibitor.administration, the percentage intragastric pH > 4 holding
time [median and range (25e75%)] were 29.3 and
19.3e50.0% with omeprazole and 27.8 and 13.0e42.3% with
lansoprazole, with the pH maintained significantly higher with
omeprazole ( p < 0.05).
The 24-hour intragastric pH (median pH per hour) profiles
after the administration of each PPI are shown in Fig. 2. After
the start of the intragastric pH measurement, administration of
omeprazole showed a rapid increase in pH. Three hours after
the start of pH measurement (i.e., at 12:30 PM), omeprazole
showed a significant increase in pH, compared with lanso-
prazole ( p < 0.05). Also at 17 and 18 hours after the start of
pH measurement (i.e., 2:30 AM and 3:30 AM), a significantly
higher pH was observed with the administration of omeprazole
compared with lansoprazole ( p < 0.05).
4. Discussion
In the treatment of GERD, rapid acid suppression is
important to control unpleasant reflux symptoms quickly.9,10
In contrast, patients with GERD tend to discontinue their
medication once their symptoms are controlled. A 2000 Gal-
lup survey showed that 45% of patients who were prescribed
omeprazole or lansoprazole once daily took the PPI substan-
tially less frequently.11 In a study conducted in the United
Kingdom, only 21% of 209 patients on long-term PPI therapy
actually complied with the once-daily regimen. Therefore,
there has been an increasingly recognized proclivity of many
reflux patients to take their medications on demand.12,13
Oral administration of omeprazole led to a rapid increase in
intragastric pH, with significantly increased pH compared with
lansoprazole at 3 hours after the start of pH measurements,
which indicates a rapid onset of the effectiveness even in the
on-demand use. In addition, while some reports have
described that nocturnal gastric acid breakthrough (NAB),
which refers to transient decrease in intragastric pH during
nighttime on PPI therapy in general and is typically observedants who were administered 20-mg omeprazole and 30-mg lansoprazole orally
the two groups). B ¼ breakfast; D ¼ dinner; L ¼ lunch; PPI ¼ proton pump
134 Y. Funaki et al. / Journal of the Chinese Medical Association 76 (2013) 131e134in H. pylori-negative patients,14,15 plays a role in the onset of
GERD.16,17 This study has demonstrated significantly
increased pH with omeprazole administration than with lan-
soprazole between 2:30 AM and 3:30 AM, thereby indicating the
beneficial effect of the administration of omeprazole against
NAB.
Based on the results from this study of single postprandial
dosing of PPIs, the usefulness of omeprazole was demon-
strated in terms of more rapid and sustained inhibition of
gastric acid secretion and reduction of NAB. Omeprazole also
appears to be suitable for patient-driven on-demand therapy
that should improve patient satisfaction with the treatment.
5. Limitations of the study
One of limitations of this studywas that therewere no data on
intragastric pH while taking these two kinds of PPIs before
breakfast. Another limitation of the study was lack of infor-
mation about CYP2C19 genetic polymorphism. Although
a previous report documented that there is no difference
between omeprazole and lansoprazole in terms of pharmacoki-
netic variations depending on CYP2C19 genetic poly-
morphism,18more detailed information of genetic polymorphism
might more precisely show their influence on intragastric pH
values. Therefore, the study result could not completely reflect
the difference of intragastric pH control between a 20-mg ome-
prazole tablet and a 30-mg lansoprazole OD.
In conclusion, in this study, we used 24-hour intragastric
pH monitoring to compare the pH in the stomach after a single
postprandial dose of a 20-mg tablet of omeprazole and
a 30-mg OD tablet of lansoprazole in a crossover manner.
Postprandial administration of omeprazole, compared with
lansoprazole, demonstrated more rapid and sustained inhibi-
tory effect on intragastric acidity.
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